Atlas Molecular Pharma will be at BIO-Europe 2026, which takes place from November 9 to 11 at Koelnmesse in Cologne, Germany. Our CEO, Susana Castel, and our Business Development Manager, Luis Ruiz-Avila, will represent the company at Europe’s largest biotech partnering conference.
The event comes only three weeks after the first three patients with Congenital Erythropoietic Porphyria (CEP) received their first dose of ATL-001 in our Phase 1/2 trial. ATL-001 is open for licensing and co-development discussions, and we look forward to meeting companies and investors interested in rare disease programs.